After 40+ Medtech Founder Conversations, Go-to-Market Consulting Really Pays Off in These Situations

For medtech founders evaluating go-to-market strategy consulting engagements, this service is one of the most consistently misframed services in the medtech commercial stack.

Founders hire consultants expecting a sales plan, a launch playbook, and a market-sizing exercise.

What the teams that compound category authority really need is market engineering. That means the eighteen-month system that produces category, messaging, narrative, and account-based motion before commercial launch.

Great companies don't wait for markets to form. They engineer them, and the medtech go-to-market strategy that closes rounds and drives commercial adoption is built on that engineering, not on a launch template.

Over 400+ episodes of State of MedTech, the pattern is consistent. Teams that treat go-to-market strategy consulting as slide-deck work end up with plans that never operationalize.

Companies that treat it as market engineering close rounds, land health system deals, and shorten sales cycles across the eighteen months before and after clearance.

Takeaways

• Go-to-market strategy consulting that closes rounds and lands health system deals is market engineering, not slide decks. Chamath's frame on the show is the underlying principle. Markets don't form after launch. They form before it, and they have to be engineered.
• Medtech founders often skip advisor selection. Bringing on one or two casual advisors before FDA clearance and then trying to build the go-to-market motion around a sales team hire after clearance is the pattern that stalls.
• Bespoke market research and de-risked customer intelligence are what real go-to-market strategy consulting for medtech delivers. Generic playbooks fail because medtech commercial dynamics don't map onto SaaS or consumer models.
• The founders and commercial leaders who compound market position early are the ones running account-based motions before commercial launch. ABM in medtech is not a lead-gen tactic. It is category-and-relationship infrastructure.
• Great companies don't wait for markets to form. They engineer them, and the go-to-market strategy consulting that supports that engineering is a completely different service than the sales-plan template most consultants sell.

Why Markets Have to Be Engineered Before Launch

That principle is the whole thesis behind an episode about why barbarians always beat bureaucrats in hardball strategy:

"Markets don't form after launch. They form before it. And in medtech, they don't just form on their own. They have to be crafted and engineered. Nobody finds you in medtech. You engineer being found."

That is the underlying principle behind medtech go-to-market strategy.

Consumer and SaaS categories often form after launch through viral distribution, network effects, or paid acquisition compounding. Medtech does not work that way.

Medtech markets are formed through specific engineering: category definition inside physician communities, market narrative repetition across trade press and podcast, and account-based motion across the specific health systems the founder is building for.

Go-to-market strategy consulting that produces value in medtech is consulting that supports that engineering. It sits upstream of the tactical sales and marketing execution most consultants deliver. It produces the market position that makes the tactical work compound instead of evaporate.

The companies that skip this engineering step arrive at commercial launch with a cleared device and no market position.

FDA clearance is the starting line, not the finish line, and clinical validation ≠ commercial traction. Consulting that produces slide decks doesn't close the traction gap that opens the moment clearance lands.

Why Skipping Advisor Selection Kills Medtech Go-to-Market Motion

This came up directly in an episode about market engineering for medtech founders:

"A lot of times I think founders skip over that. They often take their immediate like one or two or three advisers and say, 'That's good enough.' And then as soon as they are able to get through, let's say, the FDA...they're like, 'Okay, now let's do go to market. So we're going to hire sales team.'."

That sequence is the failure pattern for medtech go-to-market motion.

The advisors a founder assembles pre-clearance shape the market position, physician network, and clinical evidence package the company will bring to commercial launch. Casual advisor selection produces casual outcomes. Deliberate advisor selection produces the category authority, KOL relationships, and health system introductions the company will need eighteen months later.

Medtech leaders who assume the go-to-market work starts at clearance are already twelve months behind by the time they hire the first sales rep.

The market position that would have made the sales rep productive was supposed to be engineered by the advisor selection, clinical publication strategy, and KOL relationship investment done during the pre-clearance window.

That is the specific consulting gap medtech founders should be paying to close. Go-to-market strategy consulting that produces value works backward from commercial adoption through advisor selection, and it does that work eighteen months before clearance, not the week after.

Why Bespoke Market Research Beats Off-the-Shelf Analysis

That example came up in an episode about Edwards's big move and the $200M robotics push:

"We engage in more bespoke market research for investors, strategic startups, service providers, everyone who's focused on understanding and de-risking opportunities in medtech. we work with them to put a trusted piece of information onto their desk."

That is what real go-to-market strategy consulting for medtech looks like.

Generic industry reports, market size projections, and competitive landscape decks are the outputs of consultants who don't understand the specific dynamics of the founder's category. The reports read the same across every deliverable, and none of them de-risk the specific commercial decisions the founder is trying to make.

Bespoke market research is different.

It answers the exact question the founder needs answered. It talks to the exact physicians, health system executives, and payers the founder needs to reach. It produces trusted intelligence a strategic investor or acquirer can put on their own desk with confidence.

That is what medtech go-to-market strategy consulting should deliver at the research layer. Anything less produces slide decks the founder pays for and never really uses in a decision.

Why Account-Based Motion Beats Broad Sales and Marketing at the GTM Layer

I made this exact point in an episode about account-based marketing in medtech:

"I think the Smart Companies the smart B2B companies are going to see it as more than that and see it as more of like an actual go to market strategy like this is how sales and marketing and CS teams work together to drive our best accounts to meetings booked to qualified pipeline to bookings to revenue."

Account-based motion is the operating shape of medtech go-to-market strategy, not a marketing tactic.

The health systems, IDNs, and integrated networks a medtech company is trying to close have twelve- to twenty-four-month sales cycles. Each account has a specific clinical champion, a specific procurement path, a specific evaluation committee.

Broad marketing to a category doesn't move those accounts. Coordinated sales, marketing, and customer success motion built around the specific account structure does.

Go-to-market strategy consulting that reflects this reality produces a specific account map, a specific set of engagement tactics per named account, and a coordinated cadence across sales, marketing, and CS.

That is what medtech commercial leaders are increasingly building for. Traditional slide-deck consulting doesn't produce it because it wasn't built to.

The market-product fit at the account level is what the medtech leaders who compound category authority understand early. Every piece of content, every KOL relationship, every clinical publication is engineered toward the specific accounts that will drive commercial adoption.

Every marketing motion supports the sales motion inside those accounts, and every CS motion reinforces the market narrative underneath the customer relationship.

Why the Customer-Education Motion Compounds Faster Than Product Launch

That distinction runs through an episode about how to find early adopters in medical sales:

"My whole focus of my career was basically always helping our commercialized products...helping companies bring out their products to the customers who really need that and educate those customers about the products so that they get implemented the fastest."

Customer education is the compounding piece of medtech go-to-market motion.

Every physician champion who adopts a new device becomes an education vector for the next physician. Every health system that implements the workflow becomes a proof point for the next health system. The compounding curve is customer-driven, not marketing-driven, and it starts the moment the first accounts adopt.

Consulting that produces this outcome sits at the intersection of product, sales, and customer success. It designs the onboarding, education, and clinical evidence workflow that turns each customer into a compounding proof point.

It produces the case study library, the KOL speaking circuit content, and the peer-to-peer physician education program that make the next account easier to close than the last.

That is a completely different operating spec than a launch plan or a market entry deck. It is the go-to-market strategy consulting that really produces commercial adoption in medtech categories.

Why Most Medtech GTM Consulting Engagements Fail Mid-Way

Most medtech go-to-market consulting engagements fail somewhere between month four and month eight. The founder signs the contract expecting a launch playbook, the consultant produces one, and both sides realize by the end of the first quarter that the playbook doesn't operationalize inside the founder's specific commercial motion.

The failure mode is a mismatch between what was purchased and what was needed. The purchased deliverable was a plan document. The needed deliverable was an operating system that could compound category authority across eighteen months.

Companies that get this right restructure the engagement before signing. They ask the consultant to produce a cadence, not a plan document. They ask for weekly deliverables tied to specific market engineering outputs.

They ask for the consultant to own a specific piece of the operational stack rather than delivering a plan the founder then has to execute alone.

That restructured engagement is what medtech go-to-market strategy consulting has to look like to produce real commercial outcomes. Any lesser format produces a plan document that sits on a shelf and burns twelve months of runway.

The companies that compound category authority through consulting engagements share a specific pattern.

They pick a consulting partner willing to own operational cadence, they hold that partner to weekly market engineering outputs, and they refuse to accept plan documents as deliverables. The engagement becomes a compounding infrastructure investment instead of a slide-deck purchase.

That is the difference between medtech go-to-market strategy consulting that produces real category authority and consulting that produces a nicely formatted plan. The former closes rounds and drives adoption. The latter sits on a shelf and produces nothing durable.

What This Means for Medtech Founders

Go-to-market strategy consulting for medtech that closes rounds and drives commercial adoption is market engineering, not slide-deck production.

It requires the market narrative to be defined eighteen months before commercial launch. It requires deliberate advisor selection, bespoke market research, account-based motion at the execution layer, and a customer education workflow that turns every account into a compounding proof point.

This is the same discipline behind why hiring a healthcare marketing agency before defining your category burns 12 months of medtech runway. Fundraising strategy and go-to-market strategy are the same underlying market engineering exercise, seen through different pressure surfaces.

The teams I've watched compound both fundraising and commercial outcomes ran a coordinated program across all three of the fundraise, launch, and commercial ramp windows. Every piece of content produced during pre-clearance served both the investor conversation and the physician education workflow.

Every KOL relationship built during the fundraise contributed directly to the eventual account-based motion. Every clinical publication reinforced the category narrative on the search surface and inside the investor deck simultaneously.

That coordinated engineering is what the operators who compound category authority produce. So the go-to-market question isn't which consultant produces the best deck. It's whether the operator you hire owns the market engineering across the eighteen months before commercial launch.

If yes, the launch compounds into pipeline. If no, the launch produces impressions that never convert. That's what we built MarketCraft to solve: a market engineering practice that runs the pre-launch cadence alongside the founder, not a slide-deck vendor showing up at kickoff.

When You Start This Work Decides Which Outcome You Get

The medtech operators who understand this from the first advisor conversation reach commercial launch with a market already primed for their product.

The medtech leaders who wait until launch to start any of it reach the same commercial launch with a cleared device and no market. The consulting choice made twelve months earlier is what separates the two outcomes.

Medtech go-to-market strategy is market engineering, and market engineering compounds. The operators who stay in the game past month twelve close rounds and drive adoption. Operators who quit after the launch deck lands never see the curve turn.

Frequently Asked Questions

What Should Medtech Founders Expect From Go-to-Market Strategy Consulting?

Market engineering, not slide-deck production. The right consulting engagement produces category definition, market narrative, deliberate advisor selection, bespoke market research, account-based motion design, and customer education workflow. The wrong one produces a launch template that never operationalizes.

How Long Before Commercial Launch Should Medtech Founders Start Their Go-to-Market Strategy?

Twelve to eighteen months before clearance. The market position, advisor network, clinical evidence package, and account-based motion that drive commercial adoption are engineered during the pre-clearance window. Medtech leaders who wait until clearance to start the go-to-market work are already twelve months behind.

Why Do Generic Sales and Marketing Playbooks Fail in Medtech?

Medtech commercial dynamics don't map onto SaaS or consumer models. The sales cycles are longer, the buying committees are more complex, and the compounding pattern is customer-driven rather than marketing-driven. Playbooks that don't reflect those realities produce plans that never operationalize inside a medtech commercial motion.

What Role Does Account-Based Motion Play in Medtech Go-to-Market Strategy?

It is the operating shape of the strategy, not a marketing tactic. Every named health system, IDN, and integrated network requires coordinated sales, marketing, and customer success motion built around the specific account structure. Broad category marketing doesn't move medtech accounts. Coordinated account-based motion does.

Listen to the Full Conversations

• Why Barbarians Always Beat Bureaucrats: Hardball Strategy
• Market Engineering for Medtech Founders
• This Month in Medtech: Edwards's Big Move and the $200M Robotics Push
• How to Find Early Adopters in Medical Sales
• How to Do Account-Based Marketing in Medtech

Subscribe wherever you listen to podcasts.

About the Author

Omar Khateeb is the founder of MarketCraft and host of The State of MedTech, a leading podcast in the medtech industry.

He works with medtech founders and commercial leaders on market engineering, commercialization strategy, and revenue growth. Visit marketcraft.ai or subscribe to The State of MedTech for weekly conversations with the people building the future of medical devices.